• Nectin-4 | Bladder cancer Nectin-4 is a cell adhesion molecule and part of the Nectin family, which plays a role in the formation of cell-cell junctions. It is overexpressed in several cancers, including bladder cancer, and has emerged as a significant target in immuno-oncology. Nectin-4 is highly expressed in urothelial carcinoma, the most common type of bladder cancer. Its overexpression is associated with tumor progression and poor prognosis. Nectin-4 contributes to tumor cell proliferation, survival, and metastasis by mediating cell-cell adhesion and interacting with other signaling pathways. High levels of nectin-4 expression can be used as a diagnostic marker for bladder cancer, helping to identify patients who may benefit from targeted therapies. Overexpression of nectin-4 is correlated with more aggressive disease and poorer outcomes, making it a potential prognostic marker. Enfortumab Vedotin (Padcev) is an antibody-drug conjugate targeting nectin-4, approved for the treatment of locally advanced or metastatic urothelial carcinoma. Enfortumab vedotin consists of a monoclonal antibody specific for nectin-4 linked to a cytotoxic agent (monomethyl auristatin E, MMAE). The nectin-4 | bladder cancer concept pair shows an upward trend with a 6-fold increase in publications between 2020-2022 (Supporting Information S1).